loading...| Preferred Name |
Digitoxin |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C2634 |
| Accepted_Therapeutic_Use_For |
Atrial Fibrillation; Atrial Flutter; Congestive Heart Failure; Supraventricular Tachyarrhythmias. |
| ALT_DEFINITION |
A substance that is being studied as a treatment for cancer. |
| CAS_Registry |
71-63-6 |
| CHEBI_ID |
CHEBI:28544 |
| Chemical_Formula |
C41H64O13 |
| code |
C2634 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923 |
| Contributing_Source |
GDC FDA |
| DEFINITION |
A lipid soluble cardiac glycoside that inhibits the plasma membrane sodium potassium ATPase, leading to increased intracellular sodium and calcium levels and decreased intracellular potassium levels. In studies increased intracellular calcium precedes cell death and decreased intracellular potassium increase caspase activation and DNA fragmentation, causing apoptosis and inhibition of cancer cell growth. (NCI) |
| FDA_UNII_Code |
E90NZP2L9U |
| FULL_SYN |
DIGITOXIN Digitoxin CP4071 Cardidigin Crystalline Digitalin Crystodigin (3beta,5beta)-3-[(O-2,6-Dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-14-hydroxycard-20(22)-enolide |
| Is_Value_For_GDC_Property | |
| label |
Digitoxin |
| Legacy Concept Name |
Digitoxin |
| Maps_To |
Digitoxin |
| NCI_Drug_Dictionary_ID |
38332 |
| NSC Number |
7529 |
| PDQ_Closed_Trial_Search_ID |
38332 |
| PDQ_Open_Trial_Search_ID |
38332 |
| Preferred_Name |
Digitoxin |
| prefixIRI |
Thesaurus:C2634 |
| prefLabel |
Digitoxin |
| Semantic_Type |
Pharmacologic Substance Organic Chemical |
| UMLS_CUI |
C0012258 |
| subClassOf |